OSOlaf Stüve

Olaf Stüve

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olaf Stüve has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Bruce C. Cree

    From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California

    1 shared publication
  • Claude P. Genain

    From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California

    1 shared publication
  • Hans Christian von Büdingen

    Clinical Neuroimmunology Unit, Department of Neurology, University Hospital Zürich, Zürich, Switzerland

    1 shared publication
  • James D. Bowen

    From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California

    1 shared publication
  • Lawrence Steinman

    From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California

    1 shared publication
  • Sawsan Yousef

    From the Department of Neurology, University of California, San Francisco, California (O.S., B.C.C., H.-C.v.B., C.P.G., S.L.H., S.S.Z.); the Department of Neurology, University of Washington, Seattle, Washington (J.D.B.); and the Department of Neurology, Stanford University, Stanford, California

    1 shared publication

Latest Publications

  • Approved and Future Pharmacotherapy for Multiple Sclerosis

    by Olaf Stüve, Bruce C. Cree, Hans-Christian von Büdingen, Sawsan Yousef, James D. Bowen, Claude P. Genain, Stephen L. Hauser, Lawrence Steinman, Scott S. Zamvil

    BACKGROUND– Pharmacotherapy for relapsing-remitting multiple sclerosis (MS) advanced with the demonstration that interferon β and glatiramer acetate improve the clinical course of this disease. Mitoxantrone is the first drug approved by the Food and Drug Administration for treatment of secondary progressive MS. Despite this progress, the agents presently available are only partially effective, are difficult to administer, and may have significant side effects. Several orally administered immunomodulatory agents are presently being evaluated for treatment of MS. One class of drugs, HMG CoA inhibitors (statins), is safe and well-tolerated and could become another mainstay of MS therapy. REVIEW SUMMARY– This article reviews the clinical evidence for approved MS therapies and discusses their mechanisms of action. Furthermore, the clinical and laboratory data suggesting a potential role for statins in MS therapy are discussed. CONCLUSIONS– Although treatment with interferon β, glatiramer acetate, and mitoxantrone, the approved therapies, provide important treatment options for patients with relapsing-remitting MS and secondary progressive MS, the potential benefits of other medications, including statins, should be explored in controlled clinical trials.